ENDRA Life Sciences Q3 net loss narrows on digital asset gains
NDRA•ENDRA Life Sciences’ third-quarter net loss narrowed year over year to $1.50 million, aided by realized and unrealized digital asset gains. Operating expenses were $1.70 million, with merger-related costs rising and research and development expenses declining.
1. Quarterly results
ENDRA Life Sciences reported a third-quarter net loss of $1.50 million, narrowed year over year by realized and unrealized gains on digital assets. Operating expenses totaled $1.70 million; higher professional fees and costs tied to its proposed merger with Noble Africa were partly offset by lower research and development expenses.
2. Merger focus
The company said it remains focused on completing the proposed merger with Noble Africa and related transactions, including a $50 million private placement. Completion is subject to customary closing conditions, including stockholder approvals, and the company provided no specific financial guidance for future quarters or the full year.




